Overview

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

Status:
Suspended

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

This is an open-label study, where participants will be given ceftolozane-tazobactam as the primary treatment for Pseudomonas aeruginosa infections. Open-label means both the investigator and the participant will known what drug will be given. Participants will be followed for approximately 60 days. Ceftolozane-tazobactam is approved by the Food and Drug Administration (FDA) for treatment of serious bacterial infection and the investigator hypothesizes that ceftolozane/tazobactam may be effective as the primary antibiotic treatment for Pseudomonas aeruginosa infections.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Weill Medical College of Cornell University

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Ceftolozane
Ceftolozane, tazobactam drug combination
Tazobactam